Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients.
about
Neuro-ophthalmic side effects of molecularly targeted cancer drugs.Pimasertib-associated ophthalmological adverse events.FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.The Oxidative Stress and Mitochondrial Dysfunction during the Pathogenesis of Diabetic Retinopathy
P2860
Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Loss of MAPK Pathway Activatio ...... etinopathy in Cancer Patients.
@en
type
label
Loss of MAPK Pathway Activatio ...... etinopathy in Cancer Patients.
@en
prefLabel
Loss of MAPK Pathway Activatio ...... etinopathy in Cancer Patients.
@en
P2093
P2860
P1433
P1476
Loss of MAPK Pathway Activatio ...... Retinopathy in Cancer Patients
@en
P2093
Arthur A B Bergen
Camiel J F Boon
Danique E M Duits
Elon H C van Dijk
Gregrorius P M Luyten
Mark J de Lange
Mieke Versluis
Pieter A van der Velden
P2860
P356
10.1097/MD.0000000000003457
P407
P577
2016-05-01T00:00:00Z